Profile data is unavailable for this security.
About the company
Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, is for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. It is also developing two other clinical-stage assets, OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease, and OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease. It is conducting a pivotal Phase III clinical trial to evaluate AXPAXLI for the treatment of wet AMD. Its clinical portfolio also includes PAXTRAVA, which is in Phase III clinical development for the treatment of primary open-angle glaucoma (OAG) or ocular hypertension (OHT).
- Revenue in USD (TTM)61.10m
- Net income in USD-138.36m
- Incorporated2006
- Employees267.00
- LocationOcular Therapeutix Inc15 Crosby DriveBEDFORD 01730United StatesUSA
- Phone+1 (781) 357-4000
- Fax+1 (781) 357-4001
- Websitehttps://www.ocutx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phibro Animal Health Corp | 1.02bn | 2.42m | 902.42m | 1.94k | 374.20 | 3.52 | 23.38 | 0.8867 | 0.0595 | 0.0595 | 25.11 | 6.34 | 1.04 | 2.59 | 6.11 | 524,576.80 | 0.2473 | 3.93 | 0.3071 | 4.90 | 30.82 | 31.18 | 0.2374 | 3.77 | 1.64 | 1.76 | 0.6554 | 56.45 | 4.07 | 4.21 | -92.59 | -46.35 | 6.65 | 0.8548 |
| PetIQ Inc | 1.13bn | 13.19m | 926.28m | 1.93k | 80.85 | 3.56 | 16.44 | 0.8166 | 0.3802 | 0.3802 | 35.27 | 8.64 | 1.28 | 5.58 | 5.55 | 586,823.10 | 1.54 | -4.32 | 1.96 | -5.23 | 24.63 | 20.05 | 1.21 | -3.66 | 1.68 | 2.09 | 0.63 | -- | 19.58 | 15.83 | 104.42 | -- | 4.96 | -- |
| Evolus Inc | 237.26m | -53.21m | 1.04bn | 304.00 | -- | 54.03 | -- | 4.40 | -0.9073 | -0.9073 | 4.02 | 0.3063 | 1.18 | 4.32 | 6.58 | 869,084.30 | -26.42 | -40.92 | -34.63 | -59.74 | 69.72 | 65.43 | -22.43 | -80.46 | 2.67 | -2.00 | 0.8623 | -- | 35.98 | -- | 17.10 | -- | 182.77 | -- |
| Innoviva Inc | 330.50m | 145.42m | 1.21bn | 112.00 | 11.71 | 1.82 | 6.54 | 3.66 | 1.65 | 1.65 | 4.15 | 10.64 | 0.2821 | 1.02 | 3.78 | 2,950,857.00 | 12.41 | 26.24 | 12.78 | 28.53 | 87.06 | -- | 44.00 | 76.84 | 11.40 | -- | 0.4019 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
| ANI Pharmaceuticals Inc | 538.95m | 22.95m | 1.25bn | 642.00 | 50.17 | 2.76 | 14.73 | 2.33 | 1.19 | 1.19 | 27.93 | 22.81 | 0.6055 | 1.81 | 3.18 | 839,490.60 | 3.04 | -2.83 | 3.56 | -3.35 | 61.34 | 60.18 | 5.01 | -6.15 | 3.07 | 3.10 | 0.3725 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
| Collegium Pharmaceutical Inc | 576.65m | 99.89m | 1.26bn | 197.00 | 17.01 | 5.83 | 5.17 | 2.18 | 2.30 | 2.30 | 12.43 | 6.70 | 0.5087 | 8.14 | 3.28 | 2,927,173.00 | 8.81 | 2.79 | 14.58 | 4.80 | 61.94 | 50.88 | 17.32 | 5.16 | 1.04 | 3.69 | 0.7185 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
| Avadel Pharmaceuticals PLC (ADR) | 95.15m | -106.22m | 1.29bn | 154.00 | -- | 18.34 | -- | 13.56 | -1.17 | -1.17 | 1.04 | 0.7306 | 0.5308 | 0.6941 | 5.41 | 617,850.60 | -59.26 | -40.21 | -80.97 | -47.99 | 94.62 | -- | -111.64 | -374.75 | 2.52 | -10.25 | 0.00 | -- | -- | -22.99 | -16.59 | -- | -- | -- |
| Tarsus Pharmaceuticals Inc | 83.37m | -150.07m | 1.31bn | 244.00 | -- | 5.20 | -- | 15.75 | -4.43 | -4.43 | 2.43 | 6.63 | 0.2947 | -- | 5.36 | 341,696.70 | -53.05 | -31.56 | -60.10 | -33.82 | 92.50 | -- | -180.00 | -242.59 | 6.99 | -- | 0.221 | -- | -32.42 | -- | -118.86 | -- | 279.39 | -- |
| Ocular Therapeutix Inc | 61.10m | -138.36m | 1.40bn | 267.00 | -- | 3.70 | -- | 22.92 | -1.09 | -1.09 | 0.5249 | 2.43 | 0.191 | 2.36 | 2.12 | 228,827.70 | -43.26 | -46.70 | -47.93 | -54.18 | 90.84 | 89.36 | -226.46 | -228.65 | 16.55 | -11.30 | 0.1509 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
| Tilray Brands Inc | 788.94m | -244.98m | 1.47bn | 2.65k | -- | 0.4156 | -- | 1.87 | -0.3334 | -0.3334 | 1.06 | 4.14 | 0.185 | 2.50 | 8.40 | 297,714.00 | -5.22 | -- | -5.72 | -- | 28.31 | -- | -28.19 | -- | 1.42 | -0.9071 | 0.0963 | -- | 25.80 | -- | 83.14 | -- | -- | -- |
| Harrow Inc | 154.15m | -33.58m | 1.60bn | 315.00 | -- | 27.29 | -- | 10.36 | -0.9508 | -0.9508 | 4.38 | 1.65 | 0.581 | 4.95 | 4.39 | 489,352.40 | -12.66 | -10.86 | -14.77 | -12.71 | 71.16 | 70.75 | -21.78 | -15.35 | 2.43 | -0.3518 | 0.7608 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
| Immunocore Holdings PLC - ADR | 281.45m | -53.44m | 1.66bn | 497.00 | -- | -- | -- | 5.90 | -1.07 | -1.07 | 5.55 | -- | 0.3556 | 0.5679 | 5.56 | 566,303.60 | -6.75 | -27.55 | -8.35 | -36.82 | 99.41 | -- | -18.99 | -97.12 | 5.15 | -- | 0.5495 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
| Supernus Pharmaceuticals Inc | 630.16m | 5.24m | 1.75bn | 652.00 | 360.24 | 1.83 | 19.43 | 2.78 | 0.0883 | 0.0883 | 11.39 | 17.39 | 0.4831 | 0.9256 | 4.36 | 966,507.70 | 0.4016 | 4.95 | 0.5117 | 6.41 | 88.34 | 88.61 | 0.8314 | 12.84 | 1.69 | -- | 0.00 | -- | -8.95 | 8.24 | -97.83 | -58.81 | -8.17 | -- |
| Ligand Pharmaceuticals Inc | 133.48m | 42.14m | 1.88bn | 58.00 | 46.20 | 2.40 | 24.30 | 14.07 | 2.22 | 2.22 | 7.33 | 42.82 | 0.1643 | 0.4789 | 4.08 | 2,301,345.00 | 5.19 | 12.32 | 5.35 | 12.99 | 91.82 | 81.65 | 31.57 | 80.32 | 15.81 | -- | 0.00002 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
Data as of Sep 20 2024. Currency figures normalised to Ocular Therapeutix Inc's reporting currency: US Dollar USD
47.28%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Summer Road LLCas of 31 Mar 2024 | 14.36m | 9.27% |
| Deep Track Capital LPas of 31 Mar 2024 | 12.72m | 8.21% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 7.37m | 4.76% |
| Avoro Capital Advisor LLCas of 31 Mar 2024 | 7.15m | 4.62% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 7.00m | 4.52% |
| Opaleye Management, Inc.as of 31 Mar 2024 | 6.65m | 4.30% |
| Logos Global Management LPas of 31 Mar 2024 | 5.81m | 3.75% |
| Citadel Advisors LLCas of 31 Mar 2024 | 5.39m | 3.48% |
| Geode Capital Management LLCas of 30 Jun 2024 | 3.45m | 2.23% |
| Perceptive Advisors LLCas of 31 Mar 2024 | 3.32m | 2.15% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
